You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET fusion thyroid cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

NSCLC, Thyroid Tumors Trial (LOXO-260)

Temporarily not available
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Neoplasms
  • (no location specified)
Sep 20, 2022

Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

Active, not recruiting
Has Results
  • Solid Tumor
  • Medullary Thyroid Cancer
  • Guangzhou, Guangdong, China
  • +12 more
May 9, 2022

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

Medullary Thyroid Cancer Trial in Cordoba, Sevilla (Pralsetinib, Cabozantinib, Vandetanib)

Not yet recruiting
  • Medullary Thyroid Cancer
  • Cordoba, Spain
  • +1 more
Jan 11, 2023

NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Mar 17, 2022

Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

Recruiting
  • Thyroid Cancer
  • NTRK fusion assessment
  • Roma, Italy
    Regina Elena National Cancer Institute
Mar 31, 2023

Advanced Solid Tumor Trial (HEC169096)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Jul 6, 2022

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

    Recruiting
    • Non Small Cell Lung Cancer
    • +4 more
    • Irvine, California
    • +15 more
    Mar 9, 2022

    Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

    Recruiting
    • Lung Non-Small Cell Carcinoma
    • +4 more
    • Tampa, Florida
      Moffitt Cancer Center
    Aug 16, 2022

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

    Active, not recruiting
    • Advanced Nonhaematologic Malignancies
    • Philadelphia, Pennsylvania
    • +20 more
    Sep 23, 2022

    Pralsetinib to Best Available Therapy in RET-Fusion Positive

    Enrolling by invitation
    • RET-fusion Non Small Cell Lung Cancer
    • +16 more
      • New York, New York
      • +2 more
      Aug 9, 2021

      Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (Selpercatinib)

      Available
      • Non Small Cell Lung Cancer
      • +6 more
      • Goodyear, Arizona
      • +67 more
      Aug 17, 2022

      Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

      Recruiting
      • Medullary Thyroid Cancer
      • Birmingham, Alabama
      • +148 more
      Jan 18, 2023

      Advanced Solid Tumor Trial in Chengdu (KL590586 Capsule)

      Enrolling by invitation
      • Advanced Solid Tumor
      • KL590586 Capsule
      • Chengdu, Sichuan, China
        Sichuan Kelun Botai Biopharmaceutical Co.
      Feb 23, 2022

      Vandetanib in RET -/+ Metastatic Medullary Thyroid Cancer

      Completed
      • Symptomatic, Aggressive, Sporadic, Unresectable, Locally
      • Advanced/Metastatic Medullary Thyroid Cancer (MTC)
      • Vandetanib 300 mg
      • Belgium, Belgium
      • +7 more
      Oct 15, 2020

      NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Berazategui, Buenos Aires, Argentina
      • +195 more
      Jan 30, 2023